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Abstract
The dilemma of whether and when to start renal
replacement therapy among critically ill patients with
acute kidney injury in the absence of conventional
indications has long been a vexing challenge for
clinicians. The lack of high-quality evidence has
undoubtedly contributed decisional uncertainty
and unnecessary practice variation. Recently, two
randomized trials (ELAIN and AKIKI) reported specifically
on the issue of the timing of initiation of renal
replacement therapy in critically ill patients with acute
kidney injury. In this commentary, their fundamental
differences in trial design, sample size, and widely
discrepant findings are considered in context. While
both trials are important contributions towards
informing practice on this issue, additional evidence
from large multicenter randomized trials is needed.
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The dilemma of when to start renal replacement therapy
(RRT) among critically ill patients with acute kidney
injury (AKI) when “conventional” indications are absent
has long been a vexing challenge for clinicians [1, 2].
The lack of high-quality evidence has undoubtedly
contributed decisional uncertainty and unnecessary
practice variation [3]. Two new randomized trials
focused on the timing of RRT initiation in critically ill
patients with AKI have been reported recently [1, 2]
(Table 1).
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The Early Versus Late Initiation of Renal Replace-
ment Therapy In Critically Ill Patients With Acute Kid-
ney Injury (ELAIN) trial was a single-center trial
comparing early RRT (starting within <8 hours of ful-
filling Kidney Disease: Improving Global Outcomes
(KDIGO) stage 2 AKI) with delayed RRT (starting
within <12 hours of developing KDIGO stage 3 AKI or
upon an absolute indication) [2]. Eligible patients were
required to have blood neutrophil gelatinase-
associated lipocalin (NGAL) > 150 ng/ml and at least
one of sepsis, fluid overload, worsening Sequential
Organ Failure Assessment (SOFA) score, or receiving
vasoactive support. The trial ELAIN randomized 231
predominantly postsurgical patients. The median differ-
ence among those receiving RRT was 21 hours. Early
RRT resulted in a 15.4 % reduction in 90-day mortality
compared with delayed RRT (39.3 % vs 53.6 %; p = 0.03).
Early RRT also translated into greater kidney recovery
(53.6 % vs 38.7 %, p = 0.02; not significant after exclud-
ing deaths through 90 days), decreased RRT duration (9
vs 25 days, p = 0.04), shorter hospital stay (51 vs 82 days,
p < 0.001), and reduction in selected plasma proinflam-
matory mediators. There were no differences in organ
dysfunction scores, ICU stay, or dialysis dependence be-
yond 90 days.
The Artificial Kidney Initiation in Kidney Injury
(AKIKI) trial was a multicenter trial that compared two
strategies for starting RRT in 620 mixed critically ill
patients with AKI who were receiving mechanical
ventilation and/or vasoactives [1]. The early strategy
started RRT within <6 hours of fulfilling KDIGO stage 3
AKI and the delayed strategy started upon fulfilling
clinical criteria related to worsening AKI or complica-
tions (e.g., oligo-anuria for >72 hours; elevated urea;
hyperkalemia; metabolic acidosis; and/or pulmonary
edema from fluid overload). No difference in 60-day
mortality was found (48.5 % vs 49.7 %, p = 0.79). RRT
utilization differed significantly, with only 51 % of patients
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in the delayed strategy receiving RRT compared with 98 % in
the early strategy. The median difference for starting RRT
was 57 hours among those receiving RRT. In the delayed
strategy, RRT-free days were greater (19 vs 17 days, p < 0.001)
and the occurrence of catheter-related bloodstream infection
(CRBSI) was lower (5 % vs 10 %, p= 0.03), compared with the
early strategy. There was no difference in secondary end-
points including ventilator and vasoactive-free days through
day 28, ICU stay, hospital stay, and 60-day dialysis.
The ELAIN and AKIKI trials are important contribu-
tions towards informing practice on this issue; however,
their discordant findings necessitate careful interpretation.
Both trials were relatively small and as a result susceptible
to imprecision in effect and/or limited statistical power to
detect clinically important differences in survival that may
result from different strategies for starting RRT [4]. The
ELAIN trial was powered to detect an 18 % absolute reduc-
tion in mortality in favor of early RRT. This is an implausibly
large treatment effect for any intervention in an ICU setting.
This is further supported by a low Fragility Index of 3 (i.e.,
three more deaths in the early group or three fewer deaths
in the delayed group would render the trial nonsignificant)
[5]. Alternatively, the AKIKI trial was powered to show 15 %
absolute reduction in mortality in favor of the delayed
Table 1 Summary of recently published and ongoing randomized clinical trials evaluating optimal timing of initiation of RRT in
ICU settings
Feature STARRT-AKI (pilot) [6] ELAIN [2] AKIKI [1] IDEAL-ICU [7] STARRT-AKI (main)
Country Canada Germany France France Multiple
Number of sites 12 1 31 24 >60
Number of participants 100 231 620 864a 2866a













N/A 18 % 15 % 10 % 6 %
Control group
mortality
N/A 55 % 55 % 55 % 40 %
Interventions
Early Two of: (i) 2× increase in SCr from
baseline; (ii) UOP < 6 ml/kg in
preceding 12 hours; (iii) blood










Delayed (conservative) Specific criteria/emergent













Time difference 41.6 hoursc 25.5 hours 57.0 hours N/A N/A
Received RRT in
delayed intervention
75.0 % 90.8 % 51.0 % N/A N/A
RRT modality Physician discretion CRRT Physician discretion





Sepsis (%) 56 % N/A 67 % N/A N/A
SOFA score of
enrolled patients
~13.0 ~16.0 ~10.9 N/A N/A
Mechanical
ventilation (%)
93 % 88 % 87 % N/A N/A
Vasopressors (%) 85 % 88 % 85 % N/A N/A
Primary endpoint 90-day mortality 90-day mortality 60-day mortality 90-day mortality 90-day mortality
Early 38 % 39.3 % 48.5 % N/A N/A
Delayed 37 % 54.7 % 49.7 % N/A N/A
aPlanned enrolment
bIDEAL-ICU protocol utilizes the RIFLE classification for AKI. RIFLE-F generally aligns with KDIGO stage 3
ARR absolute risk reduction, RRT renal replacement therapy, SOFA Sequential Organ Failure Assessment, KDIGO Kidney Disease: Improving Global Outcomes,
IHD intermitted hemodialysis, N/A = not available, NGAL neutrophil gelatinase-associated lipocalin, SCr serum creatinine, UOP urine output, CRRT continuous renal
replacement therapy, RIFLE Risk, Injury, Failure, Loss, End-Stage Kidney Disease
cmean hours
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strategy. While conceivable that a delayed strategy may
translate into fewer RRT-related complications, such an ex-
pected survival difference also seems improbable.
It is debatable whether the triggers for starting RRT in
both trials reflect customary decision-making in the
ICU. The criteria used for starting RRT in the early
group of both trials and the delayed group in the ELAIN
trial were largely based on achieving creatinine and/or
urine output thresholds consistent with the KDIGO clas-
sification scheme. All participants in the early arm of the
ELAIN trial commenced RRT after stage 2 AKI and the
majority (91 %) in the delayed group started RRT, most
often upon meeting stage 3 AKI criteria. An important
consideration for clinicians is whether the triggers used
for starting RRT in these trials are in fact translatable to
routine bedside practice.
This issue was highlighted in the AKIKI trial, where the
threshold for trial enrollment, and hence receipt of RRT
in the early arm, was stage 3 AKI. During follow-up,
approximately half the patients in the delayed arm did not
receive RRT based on pre-established triggers. From this,
one may infer that a similar proportion in the early strat-
egy received RRT unnecessarily, and would have recov-
ered had they not been allocated to the early arm. These
observations highlight two key challenges for studies of
RRT timing for AKI. In the absence of objective markers
to inform a future “need” for RRT, any trial testing an
early strategy of RRT initiation will inevitably enroll some
patients who might never worsen to require RRT in a
clinical environment where a delayed or “indication-
based” approach is the standard of care. Although some
would worry about the exposure of possibly unnecessary
therapy, it should be emphasized that abundant data have
shown that “pre-emptive” RRT is prevalent in usual prac-
tice. Moreover, neither trial showed that early RRT was
incrementally harmful; although the AKIKI trial did show
a modest increase in CRBSI. These points notwithstand-
ing, we believe that the decision to start RRT in routine
practice is often based on a clinical impression shaped by
the patient’s global condition and trajectory, rather than
thresholds of creatinine or urine output alone. Integrating
the clinician’s impression regarding the likelihood of a pa-
tient needing RRT might possibly have increased the
number of patients who recovered kidney function with-
out having received RRT. More importantly, adoption of
such an approach would be more consistent with the real-
ity of clinical care which trials should strive to emulate.
The ELAIN and AKIKI trials focused attention on a
controversial issue with a noteworthy evidence care gap
and susceptibility to wide practice variation. However, due
to fundamental differences in trial design, a relatively
small sample size, and widely discrepant findings, these
studies are far from definitive. Accordingly, additional evi-
dence from large multicenter randomized trials is needed.
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